VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
You must be a Standard 1 Year member to access this content.
VISCHER acted for Artiria Medical SA on the deal. Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, closed...
You must be a Standard 1 Year member to access this content.
VISCHER advised Memo Therapeutics on the financing. Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round...
You must be a Standard 1 Year member to access this content.
VISCHER advises Epiterna with Prima Materia investment. Epiterna, a Swiss longevity company founded in 2022 by Alejandro Ocampo and Kevin Perez as a spin-off from Alejandro...
You must be a Standard 1 Year member to access this content.
Vischer advised Anokion in this transaction, while Walder Wyss advised Pfizer. Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune...
You must be a Standard 1 Year member to access this content.
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Versantis with Mark Fitzpatrick as CEO, Vincent Forster as CSO and Meriam Kabbaj as COO. Goodwin advised the sellers. Linklaters and Niederer Kraft...
You must be a Standard 1 Year member to access this content.
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings. Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. VISCHER advised Cimeo Therapeutics. Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel...
You must be a Standard 1 Year member to access this content.
Niederer Kraft Frey has advised Credit Suisse on the deal. Lenz & Staehelin advised Gilde Buy Out Partners in this transaction. VISCHER advised the co-founders and...
You must be a Standard 1 Year member to access this content.
VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...
You must be a Standard 1 Year member to access this content.
